Report Highlights

Who Controls This Market — And Who Is Threatening That Control

Novo Nordisk and Eli Lilly have built a duopoly that is structurally unusual even in pharmaceutical history. Novo Nordisk's Ozempic (semaglutide for diabetes) and Wegovy (high-dose semaglutide for obesity) generated approximately USD 21 billion in combined 2025 revenues, while Eli Lilly's Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) generated approximately USD 15 billion — a combined market position of USD 36 billion for two companies in a single drug class. The depth of their control extends beyond patent protection to manufacturing infrastructure: both companies have invested USD 10+ billion in capacity expansion for GLP-1 active pharmaceutical ingredient synthesis, creating a supply capability that no new entrant could replicate on a 5-year timeline even with unlimited capital. Novo Nordisk's acquisition of manufacturing sites in the US, Germany, and China, and Eli Lilly's USD 9 billion US manufacturing investment plan announced in 2024, are constructing physical moats as significant as their intellectual property moats.

The most credible threats to this duopoly come from three directions. Amgen's MariTide — a GIP/GLP-1 bispecific antibody — demonstrated 20% weight loss and glycaemic control in Phase 2 data with dosing intervals of six months or longer, a differentiation that could support a premium price point and address the compliance challenge that limits adherence to weekly injectable regimens. The oral GLP-1 pipeline — led by Pfizer's danuglipron and Structure Therapeutics' GSBR-1290 — could expand the addressable patient population by 200%–300% if efficacy matches injectable semaglutide, overwhelming the injectable market's scale advantage with the larger pill-taking patient population. Chinese manufacturers (Hengrui Pharmaceuticals, Haisco Pharmaceutical) are developing lower-cost GLP-1 biosimilars and novel molecules targeting the ex-US market, where branded pricing is unsustainable and generic entry timelines differ from the US schedule.

Industry Snapshot

Incretin therapies work by mimicking gastrointestinal hormones — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — that regulate insulin secretion, glucagon suppression, gastric emptying, and appetite signalling. First-generation GLP-1 agonists (exenatide, liraglutide) were approved for diabetes in the 2000s and demonstrated meaningful but modest weight loss. Second-generation compounds — semaglutide (weekly injectable and daily oral) and tirzepatide (weekly injectable, dual GLP-1/GIP agonist) — achieved 15%–22% body weight reduction in clinical trials, elevating the drug class from a diabetes adjunct to the most commercially important obesity treatment in medical history. Third-generation compounds in Phase 2 and 3 trials — triple agonists, longer-acting antibody-based approaches, oral formulations with improved bioavailability — are targeting 25%–30% weight loss with greater convenience, competing for a patient population that is 650 million adults globally by BMI classification, the largest single addressable disease population in medicine.

The Forces Accelerating Demand Right Now

Coverage expansion is the single most powerful demand driver. The Biden administration's Medicaid coverage mandate for anti-obesity medications (January 2026) added approximately 72 million potential beneficiaries to covered access, the largest single payer decision in the GLP-1 market's commercial history. The SELECT cardiovascular outcomes trial's demonstration of 20% MACE reduction has shifted payer categorisation of GLP-1s from lifestyle drugs to cardiovascular prevention medications in a growing number of insurance formularies, unlocking reimbursement that obesity indications alone could not justify in the US market's value-based coverage frameworks. International regulatory approvals — Wegovy approved in the EU, UK, Japan, Canada, Australia, and 40+ additional markets since 2022 — are expanding the total addressable patient population at a rate that existing manufacturing capacity cannot satisfy, with Novo Nordisk reporting supply constraints as a limiting factor to revenue growth through 2025.

What Is Holding This Market Back

Manufacturing capacity constraints are the most immediate commercial barrier — both Novo Nordisk and Eli Lilly have acknowledged that supply limitations, not demand, are the binding constraint on revenue growth. GLP-1 active pharmaceutical ingredient synthesis requires specialised fermentation or chemical synthesis capabilities that take 3–5 years to build at commercial scale, and the API supply chain for novel incretin molecules does not have the commoditised contract manufacturing infrastructure that small-molecule generic drugs enjoy. Payer coverage gaps remain a significant access barrier — while US employer-sponsored insurance coverage has expanded, a majority of US adults with obesity still lack coverage for anti-obesity medications, and the monthly out-of-pocket cost of USD 1,000–1,300 is prohibitive for the patient population with the highest medical need. Long-term adherence is a clinical and commercial challenge: approximately 50%–60% of patients who start GLP-1 therapy have discontinued within two years, driven by gastrointestinal side effects, injection fatigue, and the cost burden, limiting the sustained revenue per patient that the market's growth projections assume.

The Investment Case: Bull, Bear, and What Decides It

The bull case projects 170 million global patients on GLP-1 therapies by 2030 — Novo Nordisk's own internal projection, based on full coverage expansion and oral formulation approval — which at an average revenue of USD 500 per patient per month (blended between high-priced branded products in the US and lower-priced ex-US markets) implies a USD 1 trillion annual market by the early 2030s, making GLP-1 the largest pharmaceutical market category in history. Even a fraction of this projection — 50 million patients at USD 400/month average — implies a USD 240 billion annual market, more than 10× the 2024 category size.

The bear case centres on patent expiry dynamics and competing technology development. Semaglutide's US composition-of-matter patents expire from 2032, and biosimilar entry will compress branded pricing by 80%–90% over the following 3–5 years, following the pattern of insulin biosimilar market evolution. If clinical data for next-generation approaches (GLP-1/GIP/glucagon triple agonists, oral bioavailability solutions) drives a standard-of-care shift before Novo Nordisk and Eli Lilly's current products reach peak penetration, the revenue trajectory of current market leaders may plateau earlier than current consensus projections suggest. The decisive variable is the oral semaglutide approval and market uptake timeline — if Phase 3 oral formulations achieve 15%+ weight loss, they could double the addressable patient population and extend branded exclusivity through new formulation patents simultaneously.

Where the Next USD Billion Is Being Built

GLP-1 API contract manufacturing is the supply chain bottleneck that is creating manufacturing capacity as a competitive moat for both branded manufacturers and specialist CMOs. Lonza, Samsung Biologics, and WuXi Biologics have all announced GLP-1 API manufacturing expansion programmes worth USD 500 million–USD 2 billion each, capturing the production outsourcing market that the branded manufacturers cannot satisfy internally. The adjacent market opportunity in GLP-1 device delivery systems — autoinjectors, wearable patch injectors, implantable delivery devices — is a USD 8–15 billion market by 2030, with Novo Nordisk's FlexPen platform and emerging competitors offering differentiated delivery formats that address the injection fatigue driving discontinuation. The GLP-1 monitoring and companion diagnostic market — continuous glucose monitors, body composition measurement, digital therapeutics for adherence support — captures value from the long-term management infrastructure these therapies require.

Market at a Glance

Regional Intelligence

North America, and specifically the United States, accounts for approximately 65% of global GLP-1 market revenue due to the combination of highest branded drug pricing and fastest insurance coverage expansion. The US Medicaid coverage mandate and the Veterans Affairs formulary inclusion have expanded the public insurance coverage of anti-obesity GLP-1s significantly in 2025–2026. Europe is the second-largest market, with reimbursement decisions for obesity indications (as distinct from diabetes) varying substantially across national health systems — Germany's statutory insurance system began partial obesity reimbursement in 2025, while France and the UK have more restricted coverage frameworks. Asia-Pacific is the fastest-growing region in 2026–2034, driven by Japan's approval of Wegovy in 2023, China's regulatory pathway for domestic GLP-1 compounds, and the extraordinary scale of the South and Southeast Asian obesity and type 2 diabetes patient populations where GLP-1 access has historically been limited to private-pay markets.

Leading Market Participants

• Novo Nordisk
• Eli Lilly
• Amgen
• Viking Therapeutics' VK2735
• oral formulations)

Long-Term Market Perspective

The GLP-1 and incretin therapy market will be transformed by patent expiry and oral formulation approval over the 2030–2040 period. Branded injectable semaglutide and tirzepatide will face biosimilar competition from 2032–2035, compressing revenue per patient dramatically. The next commercial cycle will be driven by the oral formulation market — which at USD 100–200 per month treatment costs post-genericisation could realistically reach 300–500 million patients globally, the true mass-market penetration that current pricing precludes. Companies that own manufacturing infrastructure for both injectable and oral GLP-1 at scale, and that have built the clinical evidence base for broader indications (cardiovascular, renal, Alzheimer's, addiction), will sustain competitive positions through the branded-to-generic transition. The long-term winner in this market is the company that owns the oral high-dose formulation patents with the best efficacy-tolerability profile — the equivalent position in incretin therapy to what metformin occupies in type 2 diabetes management today.